MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "COMT inhibitors"

  • MDS Virtual Congress 2020

    Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis

    A. Lees, H. Reichmann, J.F Rocha, D. Magalhães, P. Soares-da-Silva (London, United Kingdom)

    Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…
  • MDS Virtual Congress 2020

    Effect of opicapone and entacapone on levodopa short duration response

    P. LeWitt, J. Ferreira, G. Ebersbach, E. Tolosa, G. Liang, R. Loureiro, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Detroit, MI, USA)

    Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on levodopa short duration response (SDR). Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…
  • MDS Virtual Congress 2020

    Levodopa Dose Equivalency for Opicapone and Safinamide

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, E. Natera Villalba, A. Beltran Corbellini, A. García Plata, A. Alonso Cánovas (Madrid, Spain)

    Objective: To provide a levodopa dose equivalency (LED) for opicapone and safinamide. Background: Tomlinson at al., provided a schedule to calculate LED of the different…
  • MDS Virtual Congress 2020

    Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, A. Alonso Cánovas (Madrid, Spain)

    Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…
  • MDS Virtual Congress 2020

    Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson’s disease patients with motor fluctuations

    A. Antonini, G. Ebersbach, O. Rascol, F. Ikedo, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations being treated with different levodopa-containing treatment regimens. Background: OPC,…
  • MDS Virtual Congress 2020

    Opicapone management: A 2-year follow up real- life practice study

    M. Mata, C. Borrue, M. Almarcha (Madrid, Spain)

    Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed…
  • 2019 International Congress

    Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom

    V. Leta, D. van Wamelen, A. Sauerbier, S. Jones, A. Podlewska, D. Trivedi, M. Parry, P. Odin, A. Storch, Z. Pirtošek, A. Antonini, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To investigate whether the use of Opicapone as an add-on therapy to levodopa-carbidopa intestinal gel (LCIG) infusion in advanced Parkinson’s disease (PD) reduces the…
  • 2019 International Congress

    Effect of Once-Daily Opicapone on the Pharmacokinetics of Repaglinide

    G. Loewen, G. Liang, R. Jimenez, K. Olson, E. Smith, H. Bozigian (San Diego, CA, USA)

    Objective: To evaluate the effect of once-daily administration of opicapone 50 mg on the pharmacokinetics (PK) of repaglinide. Background: Opicapone, a highly selective catechol-O-methyltransferase (COMT)…
  • 2019 International Congress

    Impact of repeated oral administration of Opicapone on the plasma pharmacokinetics of levodopa

    M. Nomoto, A. Takeda, K. Iwai, A. Nishimura, N. Hattori (Ehime, Japan)

    Objective: To examine the inhibitory effect of COMT on the plasma pharmacokinetics of levodopa resulting from repeated, once daily, oral administration of an Opicapone (OPC)…
  • 2019 International Congress

    Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data

    R. Costa, J. Ferreira, A. Lees, E. Tolosa, W. Poewe, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

    Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley